Novartis
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Novartis inks deal with Canadian cannabis firm Tilray
December 18, 2018Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis
Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …
Novartis withdraw marketing application for heart drug
December 17, 2018Sales and Marketing CHMP, EMA, MI, Novartis, pharma
Swiss multinational Novartis has withdrawn a European Medicines Agency (EMA) marketing application for canakinumab for the prevention of serious events …
Top Ten most popular articles on Pharmafile.com this week!
December 14, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akorn, Boehringer, Novartis, Pfizer, Trump, UK, pharmafile, top 10
Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring …
FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics
December 11, 2018Manufacturing and Production, Sales and Marketing FDA, Novartis, Pear Therapeutics, app, opioid crisis, opioid epidemic, opioids, pharma, reSET-o
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS
November 29, 2018Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
Novartis’ Promacta cleared by FDA for first-line use in severe aplastic anaemia
November 19, 2018Sales and Marketing FDA, Novartis, Promacta, Revolade, US, aplastic anaemia, pharma
Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with …
Novartis denies potential split with Sandoz
November 15, 2018Business Services, Manufacturing and Production Business, M&A, MA, Novartis, Sandoz, acquisition, mergers
Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged …
Novartis’ Entresto tops enalapril in stabilised heart failure patients
November 13, 2018Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma
Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …
Novartis cuts 20% of research projects
November 1, 2018Business Services, Research and Development Business, Novartis, gene therapy, infectious diseases, research
Swiss multinational Novartis has cut a fifth of its research projects, as it abandons 90 of its 430 drug development …
Pfizer and Novartis partner up to develop combo therapies for NASH
October 29, 2018Research and Development, Sales and Marketing Novartis, Pfizer, liver, nash, pharma
Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or …
Top Ten most popular articles on Pharmafile.com this week
October 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit
Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …
Novartis snaps up cancer drug developer Endocyte for $2.1 billion
October 18, 2018Research and Development, Sales and Marketing Cancer, Endocyte, Novartis, pharma
Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
